Glenmark Pharma Net profit jumps 36pc to Rs 220 crore in Q4

The company's consolidated revenue for the quarter rose 7.96 percent to Rs 2,767.48 crore as against Rs 2,563.47 crore a year ago, Glenmark Pharmaceuticals said in a regulatory filing.

Published On 2020-06-28 04:45 GMT   |   Update On 2020-06-28 04:45 GMT

New Delhi: Glenmark Pharmaceuticals on Friday posted a 36.28 per cent increase in its consolidated net profit to Rs 220.3 crore for the fourth quarter ended March 31, 2020.

The Mumbai-based drug firm had reported a net profit of Rs 161.66 crore for the corresponding period of 2018-19.

The company's consolidated revenue for the quarter rose 7.96 per cent to Rs 2,767.48 crore as against Rs 2,563.47 crore a year ago, Glenmark Pharmaceuticals said in a regulatory filing.

For the financial year 2019-20, the company reported a consolidated net profit of Rs 775.97 crore as against Rs 924.99 crore in 2018-19.

The company's consolidated revenue for 2019-20 rose to Rs 10,640.96 crore as against Rs 98,65.46 crore recording over the previous corresponding period.

"Our growth momentum sustained in the fourth quarter despite the COVID-19 pandemic and challenging generic business environment across markets globally," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said.

The company's India, Europe and Latin America regions performed well during the quarter, he added.

"Our sustained performance has been due to the continuous efforts of all our employees around the world. Our manufacturing facilities have operated continuously and facilitated the uninterrupted supply of medicines to operating markets," Saldanha said.

Its board recommended a dividend of Rs 2.5 per share of face value of Re 1 each (250 per cent) for the financial year 2019-20.

Read also: Hindustan Unilever acquires Glenmark female hygiene brand VWash

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News